跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ENHERTU - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ENHERTU
Authorized
STANDARD
ENHERTU
astrazeneca canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
75b8e269c8ce0f69
Company
astrazeneca canada inc
Type
Standard
Approval Details
Approval Id
75b8e269c8ce0f69
Drug Approval Canada Name
ENHERTU
Product Name
ENHERTU
Status
Marketed
Status Date
2021-07-09
Original Market Date
2021-07-09
Din
02514400
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FD04 TRASTUZUMAB DERUXTECAN
Atc Name
l 01 fd 04
Aig Number
0162807001
Company Name
astrazeneca canada inc
Company Address
1004 Middlegate Road, Suite 5000, Mississauga, Ontario, Canada, L4Y 1M4
Active Ingredients
TRASTUZUMAB DERUXTECAN
100 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
75b8e269c8ce0f69
Type
Standard
Back to Health Canada Approvals